Additional file 1: Table S1. Unconditional logistic regression analysis of clinical variables associated with non-CR risk in AML patients
Additional file 8: Table S6. CR rate of different gene mutation and expression groups in intermediat...
Additional file 12: Figure S4. KaplanâMeier curves of young AML patients for OS and DFS according ...
IntroductionThe heterogeneity of treatment response in acute myeloid leukemia (AML) patients poses g...
Additional file 2: Table S2. Multivariate Cox regression analysis of clinical factors influencing AM...
Additional file 4: Table S2. Unconditional logistic regression analysis of clinical features related...
Abstract Background Cytarabine arabinoside (Ara-C) has been the core of chemotherapy for adult acute...
Additional file 8: Table S7. Combined effects of rs10786736, rs3734703 and rs8139 genotypes on survi...
Additional file 3: Table S1. Multivariate Cox regression analysis of clinical characteristics impact...
Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with 5-year disease-free surviva...
Additional file 4: Table S4. Comparison of TRM among UGT1A1 genotypes after two cycles of induction ...
Additional file 10: Table S8. Multivariate analysis of intermediate risk group (young AML patients)
Background: Acute myeloid leukemia (AML) is a heterogeneous type of blood cancer that generally affe...
Additional file 2: Figure S2. KaplanâMeier survival analysis for overall survival (OS) using diffe...
Additional file 5: Fig. S1. Impact of UGT1A1*28 or *6 on event-free survival (EFS) in AML patients. ...
Additional file 3: Table S1. FAB subgroups and cytogenetic abnormalities in AML patients
Additional file 8: Table S6. CR rate of different gene mutation and expression groups in intermediat...
Additional file 12: Figure S4. KaplanâMeier curves of young AML patients for OS and DFS according ...
IntroductionThe heterogeneity of treatment response in acute myeloid leukemia (AML) patients poses g...
Additional file 2: Table S2. Multivariate Cox regression analysis of clinical factors influencing AM...
Additional file 4: Table S2. Unconditional logistic regression analysis of clinical features related...
Abstract Background Cytarabine arabinoside (Ara-C) has been the core of chemotherapy for adult acute...
Additional file 8: Table S7. Combined effects of rs10786736, rs3734703 and rs8139 genotypes on survi...
Additional file 3: Table S1. Multivariate Cox regression analysis of clinical characteristics impact...
Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with 5-year disease-free surviva...
Additional file 4: Table S4. Comparison of TRM among UGT1A1 genotypes after two cycles of induction ...
Additional file 10: Table S8. Multivariate analysis of intermediate risk group (young AML patients)
Background: Acute myeloid leukemia (AML) is a heterogeneous type of blood cancer that generally affe...
Additional file 2: Figure S2. KaplanâMeier survival analysis for overall survival (OS) using diffe...
Additional file 5: Fig. S1. Impact of UGT1A1*28 or *6 on event-free survival (EFS) in AML patients. ...
Additional file 3: Table S1. FAB subgroups and cytogenetic abnormalities in AML patients
Additional file 8: Table S6. CR rate of different gene mutation and expression groups in intermediat...
Additional file 12: Figure S4. KaplanâMeier curves of young AML patients for OS and DFS according ...
IntroductionThe heterogeneity of treatment response in acute myeloid leukemia (AML) patients poses g...